Brevan Howard Reduces Regeneron Pharmaceuticals Stake

Hedge fund lowers position in biotech company by over 20%

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Brevan Howard Capital Management LP, a major institutional investor, has reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.6% during the third quarter, according to a recent 13F filing with the SEC. The hedge fund now owns 5,240 shares of the biopharmaceutical company's stock, valued at $2.95 million.

Why it matters

Regeneron is a prominent biotech firm known for its innovative drug discovery and development. Institutional investors closely follow changes in major stakeholder positions, as they can signal shifts in market sentiment or changes in a company's outlook.

The details

According to the 13F filing, Brevan Howard sold 1,442 shares of Regeneron Pharmaceuticals during the third quarter, lowering its total position to 5,240 shares. The hedge fund had previously owned a larger stake in the biotech company.

  • Brevan Howard reduced its Regeneron Pharmaceuticals stake during the third quarter of the year.

The players

Brevan Howard Capital Management LP

A major institutional investor and hedge fund.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Brevan Howard's Regeneron Pharmaceuticals stake could signal a shift in market sentiment or a change in the hedge fund's investment strategy, though the reasons behind the move are not entirely clear from the limited information provided.